[The not-infrequent story of a superficial bladder carcinoma...Discussion of clinical case no.2].
Gontero
Paolo
P
Urologia 1, Università degli Studi di Torino. paolo.gontero@unito.it
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000283:Administration, Intravesical; D000368:Aged; D000376:Agmatine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D001500:BCG Vaccine / Q000627:therapeutic use; D002291:Carcinoma, Papillary / Q000188:drug therapy* / Q000601:surgery; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D008297:Male; D016685:Mitomycin / Q000627:therapeutic use; D013386:Succinates / Q000627:therapeutic use; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000601:surgery; D000093542:Gemcitabine
D000276:Adjuvants, Immunologic; D000964:Antimetabolites, Antineoplastic; D001500:BCG Vaccine; C068976:MMC complex; D013386:Succinates; D003841:Deoxycytidine; D016685:Mitomycin; D000376:Agmatine; D000093542:Gemcitabine